1190 related articles for article (PubMed ID: 21871831)
1. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
4. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
5. The cardiovascular effects of GLP-1 receptor agonists.
Okerson T; Chilton RJ
Cardiovasc Ther; 2012 Jun; 30(3):e146-55. PubMed ID: 21167014
[TBL] [Abstract][Full Text] [Related]
6. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
Barnett AH
Diabetes Obes Metab; 2012 Apr; 14(4):304-14. PubMed ID: 22051096
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA; Wintle M; Kolterman O
Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
[TBL] [Abstract][Full Text] [Related]
8. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
9. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
Davidson JA
Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
[TBL] [Abstract][Full Text] [Related]
12. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M
Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
Scheen AJ
Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists.
Saraiva FK; Sposito AC
Cardiovasc Diabetol; 2014 Oct; 13():142. PubMed ID: 25338737
[TBL] [Abstract][Full Text] [Related]
17. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
18. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
19. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
Salvador J; Andrada P
Med Clin (Barc); 2014 Sep; 143 Suppl 2():28-34. PubMed ID: 25437463
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]